selected publications
- A cancer persistent DNA repair circuit driven by MDM2, MDM4 (MDMX), and mutant p53 for recruitment of MDC1 and 53BP1 on chromatin. Nucleic acids research. 2025 Academic Article GET IT
- Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment. Cancer letters. 2024 Academic Article GET IT
-
Gain-of-Function Mutant p53 R273H Interacts with Replicating DNA and PARP1 in Breast Cancer.
Cancer research.
2019
Academic Article
GET IT
Times cited: 58 - Contemplations on MDMX (MDM4) driving triple negative breast cancer circulating tumor cells and metastasis. Oncotarget. 2019 Academic Article GET IT
-
Context-dependent roles of MDMX (MDM4) and MDM2 in breast cancer proliferation and circulating tumor cells.
Breast cancer research : BCR.
2019
Academic Article
GET IT
Times cited: 32 -
Estrogen-activated MDM2 disrupts mammary tissue architecture through a p53-independent pathway.
Oncotarget.
2017
Academic Article
GET IT
Times cited: 24 -
Hot Spot Mutation in TP53 (R248Q) Causes Oncogenic Gain-of-Function Phenotypes in a Breast Cancer Cell Line Derived from an African American patient.
International journal of environmental research and public health.
2015
Academic Article
GET IT
Times cited: 18 -
Proteome-wide analysis of mutant p53 targets in breast cancer identifies new levels of gain-of-function that influence PARP, PCNA, and MCM4.
Proceedings of the National Academy of Sciences of the United States of America.
2015
Academic Article
GET IT
Times cited: 78